Log in to your Inderes Free account to see all free content on this page.
ALK-Abelló
162
DKK
+2.08 %
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
15 following
+2.08%
-2.11%
-8.99%
+7%
+60.08%
+76.37%
+5.4%
+96.01%
+369.57%
ir.alk.net
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Revenue
4.82B
EBIT %
13.81 %
P/E
73.64
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ALK B
Daily low / high price
158.1 / 162.4
DKK
Market cap
36.1B DKK
Turnover
43.02M DKK
Volume
266K
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| The Lundbeck Foundation | 40.3 % | 67.2 % |
| The Danish Labour Market Supplementary Pension ( ATP) | 7.5 % | 4.1 % |
| ALK - own shares | 1.9 % | 1.9 % |
ShowingAll content types
Nine-month interim report (Q3) 2024 (unaudited)
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio